Hepzato Kit™ (melphalan/hepatic delivery system) – New drug approval
August 14, 2023 - Delcath announced the FDA approval of Hepzato Kit (melphalan/hepatic delivery system [HDS]), as a liver-directed treatment for adult patients with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation.
Top